JNJ 10397049
a selective orexin receptor-2 antagonist
Also Known As:
1-(2,4-dibromophenyl)-3-(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)urea; JNJ 1037049; JNJ-1037049; JNJ-10397049; JNJ1037049; JNJ10397049
Networked: 2
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
1. | Okui, Rikuya:
1 article
(01/2019)
|
2. | Yamamoto, Kouichi:
1 article
(01/2019)
|
3. | Yamatodani, Atsushi:
1 article
(01/2019)
|
4. | Antolini, Marinella:
1 article
(08/2012)
|
5. | Ciccocioppo, Roberto:
1 article
(08/2012)
|
6. | Cifani, Carlo:
1 article
(08/2012)
|
7. | Corsi, Mauro:
1 article
(08/2012)
|
8. | Costantini, Vivian J A:
1 article
(08/2012)
|
9. | Di Fabio, Romano:
1 article
(08/2012)
|
10. | Martinelli, Prisca:
1 article
(08/2012)
|
Related Diseases
1. | Bulimia (Binge Eating)
08/01/2012
- " Therefore, the effects of GSK1059865 (5-bromo-N-[(2S,5S)-1-(3-fluoro-2-methoxybenzoyl)-5-methylpiperidin-2-yl]methyl-pyridin-2-amine), a selective OX(1)R antagonist, JNJ-10397049 (N-(2,4-dibromophenyl)-N'-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]urea), a selective OX(2)R antagonist, and SB-649868 (N-[((2S)-1-{[5-(4-fluorophenyl)-2-methyl-1,3-thiazol-4-yl]carbonyl}-2-piperidinyl)methyl]-1-benzofuran-4-carboxamide), a dual OX(1)/OX(2)R antagonist were evaluated in a binge eating (BE) model in female rats. "
|
2. | Anorexia
|
|
Related Drugs and Biologics